Physician profile
William Williams
NPI 1770842577
$6,332.24
in general payments reported to CMS, 2019-2025
38 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $675 · 2021: $1,348 · 2022: $958 · 2023: $568 · 2024: $1,155 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $772.43 | 2020-2025 | |
| Abbvie INC. | $759.45 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $602.58 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $584.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.77 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $451.20 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $392.06 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $268.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $209.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $202.96 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $163.53 | 2019-2022 | |
| Abbott Laboratories | $127.69 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $121.66 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $114.68 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.01 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.